Aprea Therapeutics Inc

Aprea CEO’s Zero‑Cost RSU Purchase Signals Long‑Term Confidence Amid 68% Year‑to‑Date Decline

CEO Gilad Oren’s zero‑cost RSU purchase signals confidence in Aprea Therapeutics’ p53 pipeline—insider alignment may spark a rebound as clinical milestones loom.

Aprea Therapeutics Inc
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

16/03/2026, 23:24

3 minutes to read

Aprea Executives Stack Up Stakes: CFO Buys 5,700 Shares, 5,700 Warrants in Low‑Priced Surge

Insider buying surge at Aprea Therapeutics: CFO John Hamill buys shares and warrants at $0.89, signaling management confidence amid an 80% slump.

Aprea Therapeutics Inc
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

02/02/2026, 23:03

3 minutes to read

CEO Gilad Oren Buys 28,100 Shares at $0.89 Each – Aprea Insider Confidence Amid Low-Valuation Market.

Insider buying at Aprea shows confidence amid a low valuation—discover why executives are buying at $0.89 and the potential upside for investors.

Aprea Therapeutics Inc
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

02/02/2026, 22:23

3 minutes to read